Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385866 | 0.78 | HSD11B1 (0.46) | TRPM8HSD11B1CYP3A4MEN1KMT2A | |
| SCHEMBL2975901 | 0.77 | ALDH1A1 (0.38) | TRPM8HSD11B1CYP3A4MEN1KMT2A | |
| SCHEMBL256678 | 0.75 | — | — | |
| SCHEMBL18254049 | 0.73 | — | — | |
| Fluoride SCHEMBL30330051 | 0.73 | — | — | |
| SCHEMBL10103709 | 0.72 | MEN1 (0.44) | CYP3A4MEN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL7072643 | 0.71 | — | — | |
| SCHEMBL16708778 | 0.71 | HSD11B1 (0.44) | TRPM8HSD11B1CYP3A4MEN1KMT2A | |
| Cyanide SCHEMBL30330500 | 0.70 | ALDH1A1 (0.40) | CYP3A4MEN1KMT2AALDH1A1CYP2D6 | |
| Bromide SCHEMBL27799185 | 0.70 | CYP3A4 (0.43) | CYP3A4MEN1KMT2AALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547790-B2 | Optically active 4,4-di-substituted oxazolidine derivative and method for producing same | SANKYO COMPANY, LIMITED (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20080108828-A1 | Optically Active 4,4-Di-Substituted Oxazolidine Derivative and Method for Producing Same | SANKYO COMPANY, LIMITED (JP) | 2008-05-08 | — | — | US | disclosed |
| EP-1806344-A1 | OPTICALLY ACTIVE 4,4-DISUBSTITUTED OXAZOLIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108828-A1 | Optically Active 4,4-Di-Substituted Oxazolidine Derivative and Method for Producing Same | CBR3, C9, COX6C | TRPM8 3861/4885HSD11B1 1740/4885CYP3A4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.